Ann: Positive AZD0466 clinical data presented by AstraZeneca, page-52

“I hope the announcement headline didn’t fool too many novice investors into buying in this morning. In my opinion it will be a short-lived sugar hit and the share price will duly retreat when the non-significance of this announcement sinks in.” ~ @sarge17

At 51 cents today the SP has retreated exactly as expected. Contrary to the pumping rhetoric, an interim Phase One trial update, (not ’results’, as some first thought) was never going to move the dial other than a sugar hit.

P.S. At the 2021 AGM, shareholders finally found out that viral conjunctivitis was not being pursued after 8 years of telling us otherwise.

At the 2022 AGM we found at that an Indian Viraleze deal was no longer being pursued, that there are serious problems with partner Mundipharma, and also that the market opportunity for the previous flagship drug DEP-Docetaxel is shrinking rapidly due to innovations in other drug development by competitors.

What will shareholders finally find out at the 2023 AGM?